This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Lipoprotein a (elevated)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Approximately one in people in five have an lipoprotein a plasma concentration greater than 0.3 g/l

Elevated levels of lipoprotein A is an independent risk factor for coronary artery disease

  • Lp (a) is produced in the liver; its significance lying in the fact that numerous studies have found that concentrations of plasma Lp (a) above 0.3 g/l (note reference ranges may vary between laboratories) are associated with an increased risk of coronary heart disease. This includes up to 20% of the population

    • concentrations vary from almost undetectable to greater than 1 g/l; differing little with sex, body mass index and age in adults

    • Lp(a) levels vary significantly across different ethnicities, with Africans having the highest Lp(a) levels (median 0.27 g/l ), whereas Chinese were observed to have the lowest (0.078 g/l) (3)

    • epidemiological evidence has linked Lp(a) to several cardiovascular diseases (1)

      • including myocardial infarction (MI), stroke, and aortic valve stenosis

      • findings from a Mendelian randomization study suggest that elevated Lp(a) may directly contribute to CHD development

      • among patients with ACS, raised Lp(a) levels are associated with an increased atherosclerotic burden and it identifies a subset of patients with features of high risk coronary atherosclerosis (2)

      • association between Lp(a) > 0.5g/l and MI, conferring an increased odds of MI of 48% (95% CI, 32%-67%) (3)
        • only ethnic groups that were heterogeneous were Africans and Arabs, in whom the association appeared null; however, these were the smallest subgroups and were affected by poor precision (3)
        • other evidence have revealed that Lp(a) > 0.5 g/l is a risk factor for cardiovascular disease in blacks (4)

      • evidence from FOURIER study revealed that raised Lp (a) was an independent marker of cardiovascular risk despite use of moderate or high intensity statins (5)
        • in the well-treated FOURIER cohort, in which >99% of participants received moderate- or high-intensity statins and in which LDL cholesterol was <100 mg/dL (apoB <90 mg/dL), higher Lp(a) was associated with major adverse cardiovascular events (defined as a composite of coronary heart death, MI, or urgent coronary revascularization)
          • both the third and fourth upper quartiles of the Lp(a) distribution had an increased risk of major adverse cardiovascular events of 17% and 22%, respectively, compared with the lowest quartile
  • clinical benefit of lowering Lp(a) is likely to be proportional to the absolute reduction in Lp(a) concentration. Large absolute reductions in Lp(a) of approximately 100 mg/dL may be required to produce a clinically meaningful reduction in the risk of CHD similar in magnitude to what can be achieved by lowering LDL-C level by 38.67 mg/dL (ie, 1 mmol/L) (6)

Levels may also be affected by:

  • hepatic disease and excessive alcohol decrease levels
  • diabetics with proteinuria and albuminuric renal disease have increased levels.

The pathway for clearance is uncertain.



Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.